Kalle Mattila

11PUBLICATIONS
35CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsPsychosocial aspects of childbirth and perinatal mental health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 25, 2026
Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer.

|Jun 08, 2026
Detection of disease recurrence in real-world patients with completely resected stage III cutaneous melanoma.

|Feb 10, 2026
Antibiotic treatment indicates shorter survival in patients with immunotherapy for metastatic kidney cancer.

Elisa Kankkunen, Kaisa Sunela Sunela, Timo Makkonen Makkonen

|Jul 23, 2025
Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma.

Anna Brännbäck, Ivan Mustonen, Teemu D Laajala

|Sep 30, 2024
Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study.

Kalle E Mattila, Leena Tiainen, Johanna Vikkula

|Feb 24, 2024
Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study.

Saana Virtanen, Heidi Pihlman, Maria Silvoniemi

Pageof 2

Frequent Collaborators

3 joint publications

Panu M Jaakkola

2 joint publications

Micaela Hernberg

2 joint publications

Pia Vihinen

1 joint publications

Olivia Hölsä